

James J Hsieh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8901980/publications.pdf>

Version: 2024-02-01

121
papers

11,814
citations

53939

47
h-index

34195

103
g-index

123
all docs

123
docs citations

123
times ranked

16373
citing authors

#	ARTICLE	IF	CITATIONS
1	SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes. <i>Nature Cancer</i> , 2022, 3, 188-202.	5.7	26
2	Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial. <i>Clinical Cancer Research</i> , 2022, 28, 3248-3255.	3.2	24
3	Single-cell Spatial Proteomic Revelations on the Multiparametric MRI Heterogeneity of Clinically Significant Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3478-3490.	3.2	16
4	Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4553-4553.	0.8	16
5	Lenvatinib (LEN) + pembrolizumab (PEMBRO) treatment in patients (pts) with metastatic clear cell renal cell carcinoma (RCC): Final results of a phase 1b/2 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16542-e16542.	0.8	0
6	Taspase1 orchestrates fetal liver hematopoietic stem cell and vertebrae fates through cleaving TFIIA. <i>JCI Insight</i> , 2021, 6, .	2.3	2
7	Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. <i>Lancet Oncology</i> , The, 2021, 22, 946-958.	5.1	100
8	Diagnostic Utility of RNA-Seq for Evaluation of PD-L1 Expression in Clear Cell Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021, , .	0.9	1
9	A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2021, 80, 162-170.	0.9	41
10	Structural insights into the function of the catalytically active human Taspase1. <i>Structure</i> , 2021, 29, 873-885.e5.	1.6	4
11	Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. <i>Cancer Cell</i> , 2021, 39, 1245-1261.e6.	7.7	58
12	The 2020 Prostate Cancer Issue. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 341-342.	0.9	1
13	TGF- β 2 suppresses type 2 immunity to cancer. <i>Nature</i> , 2020, 587, 115-120.	13.7	137
14	Targeting Metabolic Pathways in Kidney Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 407-418.	1.0	6
15	The 2020 Kidney Cancer Treatment Sequence Issue. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 241-243.	0.9	3
16	The 2020 nccRCC Immunotherapy Issue. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 423-424.	0.9	1
17	Elective Cytoreductive Nephrectomy After Checkpoint Inhibitor Immunotherapy in Patients With Initially Unresectable Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 361-366.	0.9	13
18	The Pan-Omics Landscape of Renal Cell Carcinoma and Its Implication on Future Clinical Practice. <i>Kidney Cancer</i> , 2020, 4, 121-129.	0.2	2

#	ARTICLE	IF	CITATIONS
19	The Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age. <i>Seminars in Nephrology</i> , 2020, 40, 28-41.	0.6	42
20	Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. <i>Scientific Reports</i> , 2020, 10, 701.	1.6	21
21	Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts. <i>Nature Communications</i> , 2020, 11, 1975.	5.8	37
22	The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 252-257.e2.	0.9	17
23	Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5008-5008.	0.8	30
24	Exploiting the circuit breaker cancer evolution model in human clear cell renal cell carcinoma. <i>Cell Stress</i> , 2020, 4, 191-198.	1.4	3
25	Integrated single-cell spatial multi-omics of intratumor heterogeneity in renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17106-e17106.	0.8	1
26	Laparoscopic cytoreductive nephrectomy is associated with significantly improved survival compared with open cytoreductive nephrectomy or targeted therapy alone. <i>Molecular and Clinical Oncology</i> , 2020, 13, 71.	0.4	0
27	PTEN Expression, Not Mutation Status in <i>TSC1</i> , <i>TSC2</i> , or <i>mTOR</i> , Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial. <i>Clinical Cancer Research</i> , 2019, 25, 506-514.	3.2	31
28	Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 373-379.e4.	0.9	33
29	Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. <i>Cell</i> , 2019, 179, 964-983.e31.	13.5	430
30	Linking Binary Gene Relationships to Drivers of Renal Cell Carcinoma Reveals Convergent Function in Alternate Tumor Progression Paths. <i>Scientific Reports</i> , 2019, 9, 2899.	1.6	13
31	Hyperpolarized MRI Visualizes Warburg Effects and Predicts Treatment Response to mTOR Inhibitors in Patient-Derived ccRCC Xenograft Models. <i>Cancer Research</i> , 2019, 79, 242-250.	0.4	27
32	Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. <i>European Urology Focus</i> , 2019, 5, 642-649.	1.6	40
33	Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 12-17.	0.8	25
34	Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma. <i>ELife</i> , 2019, 8, .	2.8	31
35	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. <i>Cell Reports</i> , 2018, 23, 313-326.e5.	2.9	523
36	Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. <i>Cell</i> , 2018, 173, 581-594.e12.	13.5	609

#	ARTICLE	IF	CITATIONS
37	BH3-dependent and independent activation of BAX and BAK in mitochondrial apoptosis. <i>Current Opinion in Physiology</i> , 2018, 3, 71-81.	0.9	55
38	In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of ¹⁸ F-(2S,4R)-4-Fluoroglutamine. <i>Radiology</i> , 2018, 287, 667-675.	3.6	80
39	Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with panomics precision. <i>Journal of Pathology</i> , 2018, 244, 525-537.	2.1	93
40	Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. <i>European Urology Focus</i> , 2018, 4, 986-994.	1.6	29
41	Are We Ready for Adjuvant Sunitinib in High-risk Renal Cell Carcinoma?. <i>European Urology</i> , 2018, 73, 69-70.	0.9	2
42	Chromosome 3p Loss Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3533-3539.	0.8	99
43	Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. <i>Lancet Oncology</i> , The, 2018, 19, 1688-1698.	5.1	119
44	Prospective Evaluation of Unprocessed Core Needle Biopsy DNA and RNA Yield from Lung, Liver, and Kidney Tumors: Implications for Cancer Genomics. <i>Analytical Cellular Pathology</i> , 2018, 2018, 1-7.	0.7	11
45	KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function. <i>Oncogene</i> , 2018, 37, 4692-4710.	2.6	102
46	Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2018, 1, 364-377.	2.6	21
47	Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2018, 74, 756-763.	0.9	144
48	Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4518-4518.	0.8	18
49	A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate Tj ETQq1 1 0.784314 rgB2p Overlo	0.8	18
50	Reply to Ye Lei, Serdar Yildiz, and Minfeng Chen's Letter to the Editor re: James J. Hsieh, David Chen, Patricia Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. <i>Eur Urol</i> 2017;71:405-414. <i>European Urology</i> , 2017, 72, e74-e75.	0.9	5
51	Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. <i>Oncologist</i> , 2017, 22, 286-292.	1.9	54
52	Renal cell carcinoma. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17009.	18.1	1,727
53	Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 532.e7-532.e13.	0.8	25
54	Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection. <i>Nature Communications</i> , 2017, 8, 15165.	5.8	61

#	ARTICLE	IF	CITATIONS
55	Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e987-e994.	0.9	39
56	The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma. <i>Cell Reports</i> , 2017, 18, 2893-2906.	2.9	153
57	SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia. <i>Blood</i> , 2017, 130, 2631-2641.	0.6	102
58	Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy. <i>Nature Communications</i> , 2017, 8, 16078.	5.8	135
59	Recommendations for the Management of Rare Kidney Cancers. <i>European Urology</i> , 2017, 72, 974-983.	0.9	36
60	Pan-urolologic cancer genomic subtypes that transcend tissue of origin. <i>Nature Communications</i> , 2017, 8, 199.	5.8	49
61	^{63}Ni Inhibits Oxidative Stress-Induced Cell Death, Including Ferroptosis, and Cooperates with the BCL-2 Family to Promote Clonogenic Survival. <i>Cell Reports</i> , 2017, 21, 2926-2939.	2.9	61
62	SWI/SNF tumor suppressor gene PBRM1/BAF180 in human clear cell kidney cancer. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1342747.	0.3	10
63	Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2017, 71, 405-414.	0.9	173
64	The difficulty in selecting patients for cytoreductive nephrectomy: An evaluation of previously described predictive models. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 35.e1-35.e5.	0.8	21
65	Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer. <i>Seminars in Cell and Developmental Biology</i> , 2017, 64, 98-106.	2.3	43
66	Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. <i>European Urology Focus</i> , 2017, 3, 590-598.	1.6	31
67	Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. <i>European Urology Focus</i> , 2017, 3, 421-427.	1.6	43
68	Persistent Severe Hyperlactatemia and Metabolic Derangement in Lethal <i>SDHB</i> -Mutated Metastatic Kidney Cancer: Clinical Challenges and Examples of Extreme Warburg Effect. <i>JCO Precision Oncology</i> , 2017, 1, 1-14.	1.5	9
69	Molecular Classification of Renal Cell Carcinoma and Its Implication in Future Clinical Practice. <i>Kidney Cancer</i> , 2017, 1, 3-13.	0.2	40
70	Benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients. <i>PLoS ONE</i> , 2017, 12, e0180350.	1.1	2
71	Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma. <i>JCI Insight</i> , 2017, 2, .	2.3	89
72	The panoramic view of clear cell renal cell carcinoma metabolism: values of integrated global cancer metabolomics. <i>Translational Andrology and Urology</i> , 2016, 5, 984-986.	0.6	7

#	ARTICLE	IF	CITATIONS
73	Therapeutic Guide for mTOuRing through the Braided Kidney Cancer Genomic River. <i>Clinical Cancer Research</i> , 2016, 22, 2320-2322.	3.2	18
74	Validation and genomic interrogation of the <scp><i>MET</i></scp> variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma. <i>Cancer</i> , 2016, 122, 402-410.	2.0	18
75	Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2016, 114, 642-649.	2.9	43
76	Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Nonâ€Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3846-3853.	0.8	69
77	MP71-06 THE IMPACT OF <i>TERT</i> PROMOTER REGION MUTATIONS IN RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2016, 195, .	0.2	1
78	Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups. <i>Cancer Immunology Research</i> , 2016, 4, 820-822.	1.6	63
79	NUP98 Fusion Proteins Interact with the NSL and MLL1 Complexes to Drive Leukemogenesis. <i>Cancer Cell</i> , 2016, 30, 863-878.	7.7	111
80	Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. <i>Genome Biology</i> , 2016, 17, 231.	3.8	746
81	A braided cancer river connects tumor heterogeneity and precision medicine. <i>Clinical and Translational Medicine</i> , 2016, 5, 42.	1.7	8
82	Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. <i>Nature Communications</i> , 2016, 7, 13131.	5.8	140
83	Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. <i>Cell Reports</i> , 2016, 14, 2476-2489.	2.9	298
84	MP73-17 SINGLE-INSTITUTIONAL ANALYSIS OF PATIENTS WITH CLEAR-CELL PAPILLARY RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2016, 195, .	0.2	1
85	MP71-07 GENETIC CONCORDANCE RATES OF MATCHED-PAIR RENAL CELL CARCINOMA SAMPLES PROVIDE EVIDENCE OF CLONAL EVOLUTION. <i>Journal of Urology</i> , 2016, 195, .	0.2	1
86	Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 56-62.	0.9	7
87	An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. <i>Cancer Cell</i> , 2016, 29, 104-116.	7.7	531
88	Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin. <i>Journal of Clinical Investigation</i> , 2016, 126, 3526-3540.	3.9	82
89	Sarcomatoid renal cell carcinoma: genomic insights from sequencing of matched sarcomatous and carcinomatous components. <i>Translational Cancer Research</i> , 2016, 5, S160-S165.	0.4	10
90	Metastatic Non-Clear Cell Renal Cell Carcinoma: An Evidence Based Review of Current Treatment Strategies. <i>Frontiers in Oncology</i> , 2015, 5, 67.	1.3	33

#	ARTICLE	IF	CITATIONS
91	Genomic characterisation of two cancers of unknown primary cases supports a kidney cancer origin. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015212685.	0.2	12
92	The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis. <i>Cell Reports</i> , 2015, 13, 1895-1908.	2.9	117
93	Taspase 1: A protease with many biological surprises. <i>Molecular and Cellular Oncology</i> , 2015, 2, e999513.	0.3	17
94	TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype. <i>Modern Pathology</i> , 2015, 28, 845-853.	2.9	127
95	PBRM1: A Critical Subunit of the SWI/SNF Chromatin Remodeling Complex. , 2015, , 111-151.		1
96	Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis. <i>Cancer Research</i> , 2015, 75, 2541-2552.	0.4	236
97	A river model to map convergent cancer evolution and guide therapy in RCC. <i>Nature Reviews Urology</i> , 2015, 12, 706-712.	1.9	49
98	Taspase1 processing alters TFIIA cofactor properties in the regulation of TFIID. <i>Transcription</i> , 2015, 6, 21-32.	1.7	8
99	An interconnected hierarchical model of cell death regulation by the BCL-2 family. <i>Nature Cell Biology</i> , 2015, 17, 1270-1281.	4.6	212
100	Taspase1-dependent TFIIA cleavage coordinates head morphogenesis by limiting Cdkn2a locus transcription. <i>Journal of Clinical Investigation</i> , 2015, 125, 1203-1214.	3.9	20
101	Taspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis. <i>Cell Research</i> , 2014, 24, 1354-1366.	5.7	29
102	Radiogenomics of Clear Cell Renal Cell Carcinoma: Associations between CT Imaging Features and Mutations. <i>Radiology</i> , 2014, 270, 464-471.	3.6	226
103	Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. <i>Genome Biology</i> , 2014, 15, 433.	3.8	69
104	Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 1955-1964.	3.2	208
105	Impact of Recurrent Copy Number Alterations and Cancer Gene Mutations on the Predictive Accuracy of Prognostic Models in Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 192, 24-29.	0.2	15
106	A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2014, 40, 533-547.	3.4	61
107	ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2014, 66, 77-84.	0.9	234
108	The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma. <i>Cancer Cell</i> , 2014, 26, 319-330.	7.7	665

#	ARTICLE	IF	CITATIONS
109	Proteasome Inhibitors Evoke Latent Tumor Suppression Programs in Pro-B MLL Leukemias through MLL-AF4. <i>Cancer Cell</i> , 2014, 25, 530-542.	7.7	40
110	The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. <i>Cancer Medicine</i> , 2014, 3, 1485-1492.	1.3	110
111	Expression of Ror2 Mediates Invasive Phenotypes in Renal Cell Carcinoma. <i>PLoS ONE</i> , 2014, 9, e116101.	1.1	20
112	A clear picture of renal cell carcinoma. <i>Nature Genetics</i> , 2013, 45, 849-850.	9.4	103
113	Clinical and Pathologic Impact of Select Chromatin-modulating Tumor Suppressors in Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2013, 63, 848-854.	0.9	198
114	SQSTM1 Is a Pathogenic Target of 5q Copy Number Gains in Kidney Cancer. <i>Cancer Cell</i> , 2013, 24, 738-750.	7.7	135
115	Cleavage of TFIIA by Taspase1 Activates TRF2-Specified Mammalian Male Germ Cell Programs. <i>Developmental Cell</i> , 2013, 27, 188-200.	3.1	31
116	Reply from Authors re: James W.F. Catto, Shahrokh F. Shariat. The Changing Face of Renal Cell Carcinoma: The Impact of Systematic Genetic Sequencing on Our Understanding of This Tumor's Biology. <i>Eur Urol</i> 2013;63:855-857. <i>European Urology</i> , 2013, 63, 857-858.	0.9	0
117	An Epidemiologic and Genomic Investigation Into the Obesity Paradox in Renal Cell Carcinoma. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1862-1870.	3.0	231
118	Novel Approaches Targeting the Vascular Endothelial Growth Factor Axis in Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 299-306.	1.0	9
119	Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators <i>BAP1</i> and <i>SETD2</i> : A Report by MSKCC and the KIRC TCGA Research Network. <i>Clinical Cancer Research</i> , 2013, 19, 3259-3267.	3.2	301
120	HGF-MET signals via the MLL-ETS2 complex in hepatocellular carcinoma. <i>Journal of Clinical Investigation</i> , 2013, 123, 3154-3165.	3.9	54
121	Proteolysis of MLL Family Proteins Is Essential for Taspase1-Orchestrated Cell Cycle Progression.. <i>Blood</i> , 2006, 108, 769-769.	0.6	3